Stay updated with breaking news from Drug Target Complexes. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The COMMODORE 2 study demonstrated that subcutaneous crovalimab every four weeks was non-inferior to intravenous eculizumab every two weeks, with comparable safety, in people new to C5 inhibitors1Monthly
The COMMODORE 2 study demonstrated that subcutaneous crovalimab every four weeks was non-inferior to intravenous eculizumab every two weeks, with comparable safety, in people new to C5... | June 9, 2023
The COMMODORE 2 study met its co-primary efficacy endpoints, showing crovalimab achieved disease control in people with paroxysmal nocturnal haemoglobinuria (PNH) who have not been previously treated with
Investegate announcements from F. Hoffmann-La Roche Ltd, Roche’s subcutaneous crovalimab given every four weeks achieves disease control in people with PNH, a life-threatening blood condition
The phase III COMMODORE 3 study of crovalimab met primary endpoints of transfusion avoidance and haemolysis control in people with paroxysmal nocturnal...